Compare AIBZ & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIBZ | AKBA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.0M | 248.3M |
| IPO Year | 2026 | 2014 |
| Metric | AIBZ | AKBA |
|---|---|---|
| Price | $2.81 | $0.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.92 |
| AVG Volume (30 Days) | 771.9K | ★ 7.5M |
| Earning Date | 11-18-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.22 | $0.54 |
| 52 Week High | $9.91 | $3.19 |
| Indicator | AIBZ | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 19.49 |
| Support Level | $2.22 | N/A |
| Resistance Level | $7.21 | $0.98 |
| Average True Range (ATR) | 0.45 | 0.05 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 31.72 | 6.81 |
Bitzero Holdings Inc is a provider of IT energy infrastructure and high-efficiency power for data centers. It focuses on data center development, Bitcoin mining, and obtaining strategic data center hosting partnerships. The company has four data center locations in the North American and Scandinavian regions, powered by clean, low-carbon energy sources. The company is driven by experience in infrastructure and a passion for positive change to become the international leader in Blockchain mining and HPC hosting in a sustainable fashion that emphasizes the long-term value proposition for all stakeholders.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.